CompletedNot Applicable

Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry

France1,027 participantsStarted 2015-09-10

Plain-language summary

A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or arterial bypass conduits with the COBRA PzF coronary stent system. The registry will primarily assess the rate of MACE (cardiac death, myocardial infarction and clinically driven target lesion revascularization.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patient has given oral consent to participate in the registry Patient is implanted with a COBRA PzF stent Target lesion(s) is/are "de novo" Exclusion Criteria: Pregnancy Age \<18 years Refusal or inability to give oral consent

What they're measuring

MACE

Timeframe: 12 months

Trial details

NCT IDNCT03103620

SponsorCeloNova BioSciences, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2017-12-31

View on ClinicalTrials.gov More Stable Angina trials